BACKGROUND: The natural history of human papillomavirus (HPV)-induced cervical cancer (CC) is not directly observable, yet the age of HPV acquisition and duration of preclinical disease (dwell time) influences the effectiveness of alternative preventive policies. We performed a Cancer Intervention and Surveillance Modeling Network (CISNET) comparative modeling analysis to characterize the age of acquisition of cancer-causing HPV infections and implied dwell times for distinct phases of cervical carcinogenesis. METHODS: Using four CISNET-cervical models with varying underlying structures but fit to common US epidemiological data, we estimated the age of acquisition of causal HPV infections and dwell times associated with three phases of cancer development: HPV, high-grade precancer, and cancer sojourn time. We stratified these estimates by HPV genotype under both natural history and CC screening scenarios, because screening prevents cancer development that affects the mix of detected cancers. RESULTS: The median time from HPV acquisition to cancer detection ranged from 17.5 to 26.0 years across the four models. Three models projected that 50% of unscreened women acquired their causal HPV infection between ages 19 and 23 years, whereas one model projected these infections occurred later (age 34 years). In the context of imperfect compliance with US screening guidelines, the median age of causal infection was 4.4-15.9 years later compared with model projections in the absence of screening. CONCLUSIONS: These validated CISNET-CC models, which reflect some uncertainty in the development of CC, elucidate important drivers of HPV vaccination and CC screening policies and emphasize the value of comparative modeling when evaluating public health policies.
BACKGROUND: The natural history of human papillomavirus (HPV)-induced cervical cancer (CC) is not directly observable, yet the age of HPV acquisition and duration of preclinical disease (dwell time) influences the effectiveness of alternative preventive policies. We performed a Cancer Intervention and Surveillance Modeling Network (CISNET) comparative modeling analysis to characterize the age of acquisition of cancer-causing HPV infections and implied dwell times for distinct phases of cervical carcinogenesis. METHODS: Using four CISNET-cervical models with varying underlying structures but fit to common US epidemiological data, we estimated the age of acquisition of causal HPV infections and dwell times associated with three phases of cancer development: HPV, high-grade precancer, and cancer sojourn time. We stratified these estimates by HPV genotype under both natural history and CC screening scenarios, because screening prevents cancer development that affects the mix of detected cancers. RESULTS: The median time from HPV acquisition to cancer detection ranged from 17.5 to 26.0 years across the four models. Three models projected that 50% of unscreened women acquired their causal HPVinfection between ages 19 and 23 years, whereas one model projected these infections occurred later (age 34 years). In the context of imperfect compliance with US screening guidelines, the median age of causal infection was 4.4-15.9 years later compared with model projections in the absence of screening. CONCLUSIONS: These validated CISNET-CC models, which reflect some uncertainty in the development of CC, elucidate important drivers of HPV vaccination and CC screening policies and emphasize the value of comparative modeling when evaluating public health policies.
Authors: Cosette M Wheeler; William C Hunt; Jack Cuzick; Erika Langsfeld; Amanda Pearse; George D Montoya; Michael Robertson; Catherine A Shearman; Philip E Castle Journal: Int J Cancer Date: 2012-06-20 Impact factor: 7.396
Authors: A Hildesheim; M H Schiffman; P E Gravitt; A G Glass; C E Greer; T Zhang; D R Scott; B B Rush; P Lawler; M E Sherman Journal: J Infect Dis Date: 1994-02 Impact factor: 5.226
Authors: Margaretha A Vink; Johannes A Bogaards; Folkert J van Kemenade; Hester E de Melker; Chris J L M Meijer; Johannes Berkhof Journal: Am J Epidemiol Date: 2013-07-28 Impact factor: 4.897
Authors: Cosette M Wheeler; William C Hunt; Nancy E Joste; Charles R Key; Wim G V Quint; Philip E Castle Journal: J Natl Cancer Inst Date: 2009-03-24 Impact factor: 13.506
Authors: N W J Bulkmans; J Berkhof; S Bulk; M C G Bleeker; F J van Kemenade; L Rozendaal; P J F Snijders; C J L M Meijer Journal: Br J Cancer Date: 2007-03-06 Impact factor: 7.640
Authors: Glen B Taksler; Elisabeth F P Peterse; Isarah Willems; Kevin Ten Haaf; Erik E L Jansen; Inge M C M de Kok; Nicolien T van Ravesteyn; Harry J de Koning; Iris Lansdorp-Vogelaar Journal: JAMA Oncol Date: 2021-06-01 Impact factor: 31.777
Authors: Megan A Smith; Emily A Burger; Alejandra Castanon; Inge M C M de Kok; Sharon J B Hanley; Matejka Rebolj; Michaela T Hall; Erik E L Jansen; James Killen; Xavier O'Farrell; Jane J Kim; Karen Canfell Journal: Prev Med Date: 2021-05-23 Impact factor: 4.637
Authors: Emi Naslazi; Jan A C Hontelez; Steffie K Naber; Marjolein van Ballegooijen; Inge M C M de Kok Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-04-09 Impact factor: 4.090
Authors: Emily A Burger; Erik El Jansen; James Killen; Inge McM de Kok; Megan A Smith; Stephen Sy; Niels Dunnewind; Nicole G Campos; Jennifer S Haas; Sarah Kobrin; Aruna Kamineni; Karen Canfell; Jane J Kim Journal: J Med Screen Date: 2021-03-17 Impact factor: 1.687
Authors: Emily A Burger; Megan A Smith; James Killen; Stephen Sy; Kate T Simms; Karen Canfell; Jane J Kim Journal: Lancet Public Health Date: 2020-02-10
Authors: Nicole G Campos; Maria Demarco; Laia Bruni; Kanan T Desai; Julia C Gage; Sally N Adebamowo; Silvia de Sanjose; Jane J Kim; Mark Schiffman Journal: Prev Med Date: 2021-03-04 Impact factor: 4.018
Authors: Adam Keane; Chiu Wan Ng; Kate T Simms; Diep Nguyen; Yin Ling Woo; Marion Saville; Karen Canfell Journal: Int J Cancer Date: 2021-08-25 Impact factor: 7.316
Authors: Inge M C M de Kok; Emily A Burger; Steffie K Naber; Karen Canfell; James Killen; Kate Simms; Shalini Kulasingam; Emily Groene; Stephen Sy; Jane J Kim; Marjolein van Ballegooijen Journal: Med Decis Making Date: 2020-06-03 Impact factor: 2.583